

Source: Okayama University (JAPAN), Public Relations and Information Strategy

For immediate release: 14 March 2016

Okayama University research: Combined gene transduction and light therapy targets gastric cancer

(Okayama, 14 March) **Photoimmunotherapy proves effective against elusive gastric cancer cells following transduction with the gene that expresses the extracellular domain protein of HER2.**

“Gastric cancer is one of the most common malignancies worldwide, making it the third leading cause of cancer-related death,” explain Michihiro Ishida, Shunsuke Kagawa and colleagues at Okayama University Graduate School of Medicine and Okayama University Hospital in Japan in a recent report. In particular they note the pernicious nature of the most common form of gastric cancer metastasis, which occurs in the peritoneum - the membrane surrounding the abdominal cavity. The researchers’ latest work targets some of the limitations of existing gastric cancer therapies, such as targeting challenges and the development of resistance to anticancer drugs.

The only known target for gastric cancer is the protein human epidermal growth factor receptor 2 (HER2). However expression of this protein tends to be low in gastric cancers and is particularly low in peritoneal cancers. To tackle this obstacle the researchers devised a viral vector that transduces into HER2-negative cells with genes expressing the extracellular domain protein for HER2. They showed the approach was effective in samples with mixed HER2-positive HER2-positive cells, as would likely be the case in peritoneal cancers.

They then administered a humanised photosensitizer drug targeted towards HER2-positive cells, originally developed by Hisataka Kobayashi at the National Institutes of Health in Maryland, US, followed up with photoimmunotherapy to selectively destroy HER2-positive cancer cells. Following the gene transduction, the photosensitizer recognised the HER2-negative cells as HER2-positive and bound to them so that the photoimmunotherapy could take effect. They demonstrated tumour suppression with this combined approach on mice that originally had HER2-negative cancer cells injected into the peritoneum.

Photoimmunotherapy attacks the cell structure, which reduces the risk of acquired resistance. In addition repeated courses enhanced the efficacy with minimal side effects. The researchers conclude, “The novel therapy of molecular-targeted photoimmunotherapy

integrated with gene transfer technology is a promising approach for the treatment of peritoneal dissemination in gastric cancer.”

## **Background**

### **Targeted drug delivery**

One of the greatest challenges in fighting cancer is avoiding damage to healthy cells, which can cause considerable sickness as a side effect of therapy. Some cancer cells can be recognised by targeting moieties, which bind to them. By functionalising therapeutic particles with these moieties the attack can be directed at cancer cells while leaving healthy cells unharmed.

The protein HER2 is overexpressed in certain types of cancer, and as such has become an important biomarker. Trastuzumab has been developed as a humanized photosensitizer that targets HER2 and seemed a good starting point for developing more effective gastric cancer treatments in the absence of other molecular-targeting gastric cancer drugs. Since the expression of HER2 is so low in peritoneal cancers (2.9%), the researchers developed a means of transducing HER2-negative cancer cells with the gene for the HER2 extracellular domain protein so that Trastuzumab would target them.


### **Viral transduction**

Viruses are infectious agents that can only replicate inside another cell. Viral reproduction by transducing viral DNA into other cells has become a useful tool for microbiologists. In the current work the researchers developed a medium-sized viral vector to transduct genes expressing HER2-extracellular-domain proteins into HER2-negative cancer cells. *Ex vivo* experiments also suggested that the gene was preferentially transduced to cancer cells on the peritoneal cavity.

One of the limitations of the current results is incomplete transduction of the gene expressing the HER2 extracellular domain protein by the adenovirus. The adenovirus developed for the transduction was engineered not to replicate, but adjustments to allow conditional replication may improve the efficacy of the treatment.

### **Photoimmunotherapy**

Cell necrosis is a form of injury that causes premature cell death. Exposure to infrared radiation can cause cell necrosis in cancer cells that have been photosensitized with Trastuzumab. As photoimmunotherapy does not require uptake of the photosensitizer inside the cancer cells it can be more effective than photodynamic therapy.



### Caption

The time course of the bioluminescence images of tumor bearing mice after treatment *in vivo* for: no treatment - control; treated with Trastuzumab-IR700 (Tra-IR700) mediated photoimmunotherapy (PIT) - IR+PIT; treated with HER2-extracellular domain transducing adenovirus (Ad/HER2-ECD) mediated PIT - Ad + PIT; and treated with Ad/HER2-ECD with Tra-IR700-mediated PIT - Ad+ IR+PIT; one dose – X1; three doses – X3

## Reference

Michihiro Ishida, Shunsuke Kagawa, Kyoko Shimoyama, Kiyoto Takehara, Kazuhiro Noma, Shunsuke Tanabe, Yasuhiro Shirakawa, Hiroshi Tazawa, Hisataka Kobayashi, and Toshiyoshi Fujiwara. Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer, *Small Molecule Therapeutics* (2016)

DOI: 10.1158/1535-7163.MCT-15-0644.

<http://mct.aacrjournals.org/content/early/2016/02/22/1535-7163.MCT-15-0644>

## Correspondence to

Associate Professor Shunsuke Kagawa, M.D., Ph.D.  
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Kita-ku, Okayama 700-8558, Japan.  
E-mail: [skagawa@md.okayama-u.ac.jp](mailto:skagawa@md.okayama-u.ac.jp)



Associate Professor  
Shunsuke Kagawa



M.D.  
Michihiro Ishida

## Further information

Okayama University  
1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan  
Public Relations and Information Strategy  
E-mail: [www-adm@adm.okayama-u.ac.jp](mailto:www-adm@adm.okayama-u.ac.jp)  
Website: [http://www.okayama-u.ac.jp/index\\_e.html](http://www.okayama-u.ac.jp/index_e.html)  
Okayama Univ. e-Bulletin: <http://www.okayama-u.ac.jp/user/kouhou/ebulletin/>  
Okayama Univ. e-Bulletin (PDF Issues): <http://www.okayama-u.ac.jp/en/tp/cooperation/ebulletin.html>  
About Okayama University (You Tube):  
<https://www.youtube.com/watch?v=iDL1coqPRYI>  
Okayama University Image Movie (You Tube):  
<https://www.youtube.com/watch?v=WnbJVk2eIA>  
<https://www.youtube.com/watch?v=KU3hOIXS5kk>

## Okayama University Medical Research Updates (OU-MRU)

- Vol.1 : [Innovative non-invasive 'liquid biopsy' method to capture circulating tumor cells from blood samples for genetic testing](#)
- Vol.2 : [Ensuring a cool recovery from cardiac arrest](#)
- Vol.3 : [Organ regeneration research leaps forward](#)
- Vol.4 : [Cardiac mechanosensitive integrator](#)
- Vol.5 : [Cell injections get to the heart of congenital defects](#)
- Vol.6 : [Fourth key molecule identified in bone development](#)

- Vol.7 : [Anticancer virus solution provides an alternative to surgery](#)
- Vol.8 : [Light-responsive dye stimulates sight in genetically blind patients](#)
- Vol.9 : [Diabetes drug helps towards immunity against cancer](#)
- Vol.10 : [Enzyme-inhibitors treat drug-resistant epilepsy](#)
- Vol.11 : [Compound-protein combination shows promise for arthritis treatment](#)
- Vol.12 : [Molecular features of the circadian clock system in fruit flies](#)
- Vol.13 : [Peptide directs artificial tissue growth](#)
- Vol.14 : [Simplified boron compound may treat brain tumours](#)
- Vol.15 : [Metamaterial absorbers for infrared inspection technologies](#)
- Vol.16 : [Epigenetics research traces how crickets restore lost limbs](#)
- Vol.17 : [Cell research shows pathway for suppressing hepatitis B virus](#)
- Vol.18 : [Therapeutic protein targets liver disease](#)
- Vol.19 : [Study links signalling protein to osteoarthritis](#)
- Vol.20 : [Lack of enzyme promotes fatty liver disease in thin patients](#)

### About Okayama University

Okayama University is one of the largest comprehensive universities in Japan with roots going back to the Medical Training Place sponsored by the Lord of Okayama and established in 1870. Now with 1,300 faculty and 14,000 students, the University offers courses in specialties ranging from medicine and pharmacy to humanities and physical sciences.

Okayama University is located in the heart of Japan approximately 3 hours west of Tokyo by Shinkansen.

